8-K: Tenax Therapeutics Enrolls First Patient in Phase 3 Trial for Pulmonary Hypertension Treatment

Tenax Therapeutics has announced the enrollment of the first patient in its Phase 3 LEVEL study evaluating TNX-103 for pulmonary hypertension associated with heart failure with preserved ejection fraction.

Summary

• Tenax Therapeutics has initiated its Phase 3 LEVEL study, enrolling the first patient to evaluate TNX-103 (oral levosimendan) for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).
• The LEVEL study is a randomized, controlled trial involving 152 patients across over 40 sites in the U.S. and Canada.
• Topline data from the LEVEL study is expected to be available in the second half of 2025.
• The primary endpoint of the study is the six-minute walk distance (6MWD) at week 12.
• The study will evaluate oral levosimendan at 2 mg/day for weeks 1-4 and 3 mg/day for weeks 5-12.
• The FDA does not require a long-term cardiovascular outcomes trial for this drug, reducing costs and time for registration.
• The levosimendan patent estate provides protection through at least 2040 for all therapeutic doses of the oral formulation being evaluated.

Sentiment

Score: 8

Explanation: The document is positive due to the initiation of a Phase 3 trial, the lack of requirement for a long-term outcomes trial, and strong patent protection. However, there are still risks associated with clinical trials and regulatory approvals.

Positives

• The initiation of the Phase 3 LEVEL study is a significant milestone for Tenax Therapeutics.
• The FDA's decision not to require a long-term cardiovascular outcomes trial will save time and money.
• The strong patent protection for levosimendan provides a competitive advantage.
• The participation of leading research centers and investigators indicates confidence in the drug's potential.
• The study is designed to exceed the minimal clinically important difference and meet FDA requirements for drug exposure.

Risks

• The company's business strategy and prioritization of product candidates could impact results.
• There are risks associated with clinical trials, including timing, delays, costs, design, and results.
• Regulatory review and approval of product candidates could face delays.
• The company relies on third parties, including Orion Corporation, manufacturers, and CROs.
• There are risks related to the formulation, production, marketing, customer acceptance, and clinical utility of product candidates.
• The company's ability to raise additional money to fund operations is a risk.
• Intellectual property risks could impact the company.
• The company's continued listing on Nasdaq is a risk.
• Global economic and financial market volatility could impact the company.
• Changes in legal, regulatory, and legislative environments could impact the company.

Future Outlook

Tenax forecasts topline data from the LEVEL study will be available in the second half of 2025.

Management Comments

• Chris Giordano, President and CEO, stated they are pleased to announce the enrollment of the first patient and are progressing rapidly from identification to initiation of investigator sites.
• Stuart Rich, M.D., Chief Medical Officer, mentioned they are thrilled to be working with some of the largest, most prestigious cardiovascular research institutes in North America.

Industry Context

This announcement is significant as there are currently no FDA-approved drugs for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), highlighting a substantial unmet medical need. The successful development of TNX-103 could position Tenax as a leader in this therapeutic area.

Comparison to Industry Standards

• The Phase 3 trial design, focusing on the six-minute walk distance, is a common endpoint in pulmonary hypertension studies, aligning with industry standards.
• The planned enrollment of 152 patients is typical for a Phase 3 trial of this nature.
• The use of a placebo-controlled design is a standard approach for evaluating drug efficacy.
• The fact that nine of ten investigators from a previous levosimendan study have agreed to participate in the LEVEL study suggests a high level of confidence in the drug's potential, which is a positive sign compared to other trials where investigator buy-in may be lower.
• The FDA's decision not to require a long-term cardiovascular outcomes trial is a significant advantage for Tenax, as such trials are often costly and time-consuming, and this is not typical for all drug approvals in this space.

Stakeholder Impact

• Shareholders may see a positive impact due to the progress of the clinical trial.
• Patients with PH-HFpEF may benefit from a new treatment option.
• Employees of Tenax Therapeutics are working towards a significant milestone.
• Research partners and CROs are involved in the study's execution.

Next Steps

• Continue patient enrollment in the Phase 3 LEVEL study.
• Monitor patient progress and collect data.
• Analyze topline data expected in the second half of 2025.
• Potentially pursue regulatory approval for TNX-103.

Key Dates

Keywords

pulmonary hypertension, heart failure, levosimendan, TNX-103, Phase 3 trial, PH-HFpEF, cardiovascular, clinical trial, FDA, pharmaceutical